Showing results (61-70 of 130) with videos related to
Sort By:
Pageof 13
Prostate Cancer and Prostatic Diseases|June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trialQuoc-Dien Trinh, Daniel J George, Neal Shore, et al.European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.Cancer Chemotherapy and Pharmacology|February 7, 2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumorsShahneen K Sandhu, Kyri Papadopoulos, Peter C Fong, et al.Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerHoward I Scher, Glenn Heller, Arturo Molina, et al.JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.Pageof 13